Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FUROSCIX vs BUMEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Treatment of edema associated with congestive heart failure,Treatment of edema associated with cirrhosis of the liver,Treatment of edema associated with renal disease including nephrotic syndrome
Edema associated with congestive heart failure,Edema associated with hepatic cirrhosis,Edema associated with renal disease including nephrotic syndrome
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (Cr Cl <30 m L/min) and 9-19 hours in anuria
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (Cr Cl <20 m L/min).
Furosemide is primarily metabolized by glucuronidation via UGT1A1, UGT1A9, and UGT2B7; to a lesser extent by cytochrome P450 enzymes.
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
91-99%, primarily to albumin
Bumetanide is 94–96% bound to plasma proteins (primarily albumin).
0.1-0.2 L/kg; higher in neonates (0.2-0.4 L/kg); restricted to extracellular fluid in adults
0.15–0.22 L/kg; indicates primarily extracellular distribution.
Subcutaneous: 99% compared to IV; oral: 60-70% (variable due to first-pass metabolism)
Oral bioavailability: 80–100% (mean ~95%).
e GFR 15-29 m L/min/1.73m2: 40 mg subcutaneously once daily. e GFR <15 m L/min: not recommended. e GFR ≥30: no adjustment needed.
e GFR <20 m L/min/1.73 m²: Avoid loop diuretics; consider alternative. No adjustment for mild to moderate renal impairment, but monitor response. In severe renal failure, may require higher doses due to reduced tubular secretion.
Child-Pugh A or B: no adjustment. Child-Pugh C: use with caution; reduce dose to 40 mg subcutaneously once daily. No specific pharmacokinetic data in severe impairment.
Child-Pugh Class B or C: Reduce initial dose by 50% due to impaired metabolism and increased risk of volume depletion. Titrate cautiously.
Safety and efficacy not established in pediatric patients (<18 years). No approved dosing available.
Infants/Children: Oral: 0.015-0.1 mg/kg/dose once daily; maximum 10 mg/day. IV/IM: 0.015-0.1 mg/kg/dose every 12-24 hours; maximum 0.5 mg/kg/dose. Neonates: 0.01-0.05 mg/kg/dose every 24-48 hours.
Start at 40 mg subcutaneously once daily. Monitor renal function and electrolyte levels closely. Consider lower doses due to age-related decreased renal function.
Start at 0.5 mg orally once daily; increase cautiously due to enhanced pharmacodynamic effects and higher risk of electrolyte disturbances, volume depletion, and ototoxicity. Monitor renal function and electrolytes closely.
Furosemide can cause profound diuresis with water and electrolyte depletion, leading to serious adverse events such as circulatory collapse and thromboembolic complications. Careful medical supervision is required.
Bumetanide is a potent diuretic; if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule must be adjusted to individual patient's needs.
Monitor for electrolyte disturbances (e.g., hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia),May cause ototoxicity, especially with rapid injection or high doses,Risk of renal impairment; monitor renal function,Can exacerbate systemic lupus erythematosus,Avoid in patients with known sulfonamide allergy
Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypovolemia,Ototoxicity (especially with rapid injection or in renal impairment),Excessive diuresis causing hypotension and thromboembolic events,May increase serum uric acid levels and precipitate gout,Risk of hypokalemia in patients with cirrhosis and ascites
Anuria,Severe hypokalemia,Severe hyponatremia,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or pre-coma
Anuria,Hepatic coma or severe electrolyte depletion until condition is corrected,Hypersensitivity to bumetanide or sulfonamides (cross-sensitivity possible)
Avoid foods high in sodium (e.g., processed meats, canned soups) to reduce fluid retention. No significant food-drug interactions. May increase potassium and magnesium loss; ensure adequate intake of potassium-rich foods (e.g., bananas, oranges) but monitor levels closely.
Avoid excessive salt intake; no specific food interactions reported. Avoid licorice as it may worsen hypokalemia. Grapefruit juice may increase bumetanide levels; use caution.
Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause maternal hypovolemia, reduced placental perfusion, and fetal oligohydramnios; avoid if possible. Not associated with major congenital malformations.
Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are limited; no well-controlled studies exist. First trimester: theoretical risk based on animal data; avoid unless essential. Second/third trimesters: may cause maternal hypovolemia, decreased placental perfusion, and fetal oliguria; use only if clearly needed and monitor amniotic fluid volume. Neonatal risks include electrolyte imbalances and ototoxicity if used close to delivery.
Furosemide is excreted into human breast milk in low amounts (M/P ratio approximately 0.2-0.5). Peak milk concentration ~0.4-0.6 µg/m L after 40 mg oral dose. Limited data suggest no adverse effects in breastfed infants. Use with caution, especially in neonates due to risk of diuresis and electrolyte imbalance.
Bumetanide is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05-0.10. Based on limited data, amounts ingested by breastfed infants are unlikely to cause adverse effects. However, due to potential risk of hypersensitivity, electrolyte disturbances, or diuresis in the infant, caution is advised, especially in premature or renal-impaired infants. Alternative diuretics with more safety data may be preferred.
Furosemide pharmacokinetics may be altered in pregnancy due to increased volume of distribution and renal clearance. Lower doses may achieve desired diuresis; start at low end of dosing range (20-40 mg/day oral) and titrate based on clinical response and monitoring. Avoid high doses and prolonged use due to risk of hypovolemia and placental hypoperfusion.
Pregnancy may alter bumetanide pharmacokinetics due to increased plasma volume, renal blood flow, and glomerular filtration rate. Higher doses may be required to achieve the same diuretic effect. However, no standard dose adjustment guidelines exist; use the lowest effective dose and titrate based on clinical response, monitoring for electrolyte disturbances and volume depletion. In severe preeclampsia or renal impairment, dose may need reduction. Close therapeutic drug monitoring is not routinely available; clinical monitoring of diuresis and electrolytes guides dosing.
FUROSCIX (furosemide) is a subcutaneous loop diuretic for heart failure congestion. Onset of diuresis within 30 minutes; peak effect at 1-2 hours. Monitor for hypokalemia, hypomagnesemia, and ototoxicity. Use with caution in sulfonamide allergy. Avoid concurrent use with NSAIDs as they reduce diuretic efficacy.
Bumetanide is a loop diuretic approximately 40 times more potent than furosemide; onset of diuresis within 30-60 minutes after oral administration. Monitor for ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Hypokalemia is a common adverse effect; consider potassium supplementation or concurrent use of potassium-sparing diuretics. Contraindicated in anuria, hepatic coma, and severe electrolyte depletion. May cause hyperuricemia and precipitate gout attacks.
Inject subcutaneously into the abdomen; rotate sites.,Take in the morning to avoid nocturia.,Monitor daily weight and report >2 lb/day gain.,Report hearing changes, ringing in ears, or dizziness.,Avoid excessive salt intake; limit alcohol.,Do not use with NSAIDs or lithium without doctor approval.
Take this medication exactly as prescribed, typically once daily in the morning to avoid nighttime urination.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Do not consume grapefruit juice or alcohol while taking this drug.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or confusion.,Weigh yourself daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FUROSCIX vs BUMEX, answered by our medical review team.
FUROSCIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.. BUMEX is a Loop Diuretic that works by Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FUROSCIX and BUMEX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FUROSCIX is: 80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.. The standard adult dose of BUMEX is: 0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FUROSCIX and BUMEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FUROSCIX is classified as Category C. Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause. BUMEX is classified as Category C. Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are l. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.